סלסול תמידי (פרמננט) קר - מספר 2 לשיער צבוע וטבעי
גילעם הכל לספר בעמ - צביעת שיער
אמיודקור זריקות
sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.
פרינל תרסיס
trupharm marketing 1985 ltd. - hydrocortisone; lidocaine as hydrochloride - ספריי - hydrocortisone 0.2 %w/w; lidocaine as hydrochloride 1 %w/w - hydrocortisone - hydrocortisone - for the symptomatic relief of anal and perianal pain and pruritis such as associated with haemorrhoids.
אלדרה % 5
megapharm ltd - imiquimod - קרם - imiquimod 5 % - imiquimod - imiquimod - indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients. for the treatment of actinic keratoses in adults with normal immune systems. for the treatment of superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.
אקווימוד קרם % 5
taro pharmaceutical industries ltd - imiquimod - קרם - imiquimod 5 % - imiquimod - imiquimod - indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients. for the treatment of actinic keratoses in adults with normal immune systems. for the treatment of superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.
פרימוד
perrigo israel pharmaceuticals ltd - imiquimod - קרם - imiquimod 5 % - imiquimod - imiquimod - indicated for the topical treatment of external genital and perianal warts (condyloma acuminata) in adult patients. for the treatment of actinic keratoses in adults with normal immune systems. for the treatment of superficial basal cell carcinoma in adults with normal immune systems when surgical methods are less appropriate.
וריג'ן % 10
abic marketing ltd - polyphenon e 10 %w/w - ointment - cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years.